
Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.
The partnership builds upon an existing research collaboration between the two companies. Under the terms of the new deal, 2Seventy Bio receives an upfront payment of USD 5m, and the company is eligible for milestone payments of up to USD 35m as well as potential royalties from sales of the drug.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app